Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial

NCT03584308 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.

NCT NCT03584308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03584308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial
Lead sponsor
Catalysis SL
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2015
Completion date
December 15, 2018
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal verrucous carcinoma, esophageal viral wart, papilloma viral infection, papillomavirus infections